

Referansen er hentet fra følgende kilder:  
National Center for Biotechnology Information (NCBI)  
PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>)

[Gan To Kagaku Ryoho](#). 2012 Nov;39(12):1779-81.

## **[Evaluation of quality of life and immune function in cancer patients receiving combined immunotherapy and oral administration of lentinula edodes mycelia extract].**

[Article in Japanese]

[Tanigawa K](#), [Ito Y](#), [Sakai M](#), [Kobayashi Y](#).

### **Source**

Tokyo Women's Medical University, Tokyo, Japan.

### **Abstract**

Lentinula edodes mycelia extract(LEM) may mitigate the immunosuppression caused by regulatory T cells(Tregs), and it is therefore expected that LEM will be useful with cancer immunotherapy. In this study, we evaluated the quality of life (QOL) and immune function in cancer patients receiving a combination of immunotherapy and oral administration of LEM.

### **METHODS:**

Ten patients who had received cancer immunotherapy were enrolled. They received cancer immunotherapy alone for the first 4 weeks, and were then administered LEM (1,800 mg/day) with cancer immunotherapy for the next 4 weeks. QOL scores and immune parameters were evaluated at weeks 0, 4, and 8.

### **RESULTS:**

The total score for QOL was improved during the period with LEM administration compared to the period with immunotherapy alone. Interferon (IFN)- $\gamma$  secretion from peripheral blood cells was increased during the period with LEM administration. The change in IFN- $\gamma$  secretion in the LEM administration period possibly correlated with changes in the Treg population.

### **CONCLUSION:**

Oral administration of LEM may improve QOL and immunity in patients receiving cancer immunotherapy.

PMID:

23267884

[PubMed - indexed for MEDLINE]